| Literature DB >> 17986100 |
A Shibata-Hamaguchi1, M Samuraki, E Furui, K Iwasa, H Yoshikawa, S Hayashi, M Yamada.
Abstract
Anti-muscle-specific receptor tyrosine kinase (MuSK) antibody-positive myasthenia gravis (MG) patients show various responses to conventional immunosuppressive treatment and some patients are resistant to these therapies. We report a 50-year-old Japanese man with anti-MuSK antibody-positive MG, who showed no or poor response to various therapies, including plasmapheresis, corticosteroid, and tacrolimus. The patient was then treated with intravenous immunoglobulin (IVIG), and showed a good response that persisted over 20 months. The outcome of this case suggests that IVIG treatment may be an effective therapeutic option for anti-MuSK antibody-positive MG, with a potentially long-term effect.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17986100 DOI： 10.1111/j.1600-0404.2007.00877.x
Source DB: PubMed Journal: Acta Neurol Scand ISSN： 0001-6314 Impact factor: 3.209